Maria da Conceição Viana Invenção

Ms. Maria da Conceição Viana Invenção

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
FSFernanda Lays Souza Góes Santos
Fernanda Lays Souza Góes Santos
MIMaria da Conceição Viana Invenção
Maria da Conceição Viana Invenção
EAEdilaine Dória Araújo
Edilaine Dória Araújo
GBGerlane dos Santos Barros
Gerlane dos Santos Barros
Marcus BatistaMarcus Batista
Marcus Batista

4 December 2022 in Genes
Verified
Journal Article
Open access
PDF file
AMAlanne Rayssa Da Silva Melo
Alanne Rayssa Da Silva Melo
Larissa Silva de MacêdoLarissa Silva de Macêdo
Larissa Silva de Macêdo
MIMaria da Conceição Viana Invenção
Maria da Conceição Viana Invenção
Ingrid Andrêssa de MouraIngrid Andrêssa de Moura
Ingrid Andrêssa de Moura
MGMarco Turiah Gama
Marco Turiah Gama
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
Gene immunization comprises mRNA and DNA vaccines, which stand out due to their simple design, maintenance, and high efficacy. Several studies indicate promising results in preclinical and clinical trials regarding immunization against ebola, human immunodeficiency virus (HIV), influenza, and human papillomavirus (HPV). The efficiency of nucleic acid vaccines has been highlighted in the fight against COVID-19 with unprecedented approval of their use in humans. However, their low intrinsic immunogenicity points to the need to use strategies capable of overcoming this characteristic and increasing the efficiency of vaccine campaigns. These strategies include the improvement of the epitopes’ presentation to the system via MHC, the evaluation of immunodominant epitopes with high coverage against emerging viral subtypes, the use of adjuvants that enhance immunogenicity, and the increase in the efficiency of vaccine transfection. In this review, we provide updates regarding some characteristics, construction, and improvement of such vaccines, especially about the production of synthetic multi-epitope genes, widely employed in the current gene-based vaccines.

11 August 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
ASAnna Jéssica Duarte Silva
Anna Jéssica Duarte Silva
Ingrid Andrêssa de MouraIngrid Andrêssa de Moura
Ingrid Andrêssa de Moura
MGMarco Turiah Gama
Marco Turiah Gama
LLLígia Rosa Sales Leal
Lígia Rosa Sales Leal
SPSamara Sousa de Pinho
Samara Sousa de Pinho
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
The understanding of the relationship between immunological responses and cancers, especially those related to HPV, has allowed for the study and development of therapeutic vaccines against these neoplasias. There is a growing number of studies about the composition and influence of the tumor microenvironment (TME) in the progression or establishment of the most varied types of cancer. Hence, it has been possible to structure immunotherapy approaches based on therapeutic vaccines that are even more specific and directed to components of TME and the immune response associated with tumors. Among these components are dendritic cells (DCs), which are the main professional antigen-presenting cells (APCs) already studied in therapy strategies for HPV-related cancers. On the other hand, tumor-associated macrophages are also potential targets since the profile present in tumor infiltrates, M1 or M2, influences the prognosis of some types of cancer. These two cell types can be targets for therapy or immunomodulation. In this context, our review aims to provide an overview of immunotherapy strategies for HPV-positive tumors, such as cervical and head and neck cancers, pointing to TME immune cells as promising targets for these approaches. This review also explores the potential of immunotherapy in cancer treatment, including checkpoint inhibitors, cytokine immunotherapies, immunotherapy vaccines, and cell therapies. Furthermore, it highlights the importance of understanding the TME and its effect on the design and achievement of immunotherapeutic methods.

30 November 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
Ingrid Andrêssa de MouraIngrid Andrêssa de Moura
Ingrid Andrêssa de Moura
ASAnna Jéssica Duarte Silva
Anna Jéssica Duarte Silva
Larissa Silva de MacêdoLarissa Silva de Macêdo
Larissa Silva de Macêdo
MIMaria da Conceição Viana Invenção
Maria da Conceição Viana Invenção
MSMylenna Máyra Gois de Sousa
Mylenna Máyra Gois de Sousa
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
Prophylactic vaccines against human papillomavirus (HPV) have proven efficacy in those who have not been infected by the virus. However, they do not benefit patients with established tumors. Therefore, the development of therapeutic options for HPV-related malignancies is critical. Third-generation vaccines based on nucleic acids are fast and simple approaches to eliciting adaptive immune responses. However, techniques to boost immunogenicity, reduce degradation, and facilitate their capture by immune cells are frequently required. One option to overcome this constraint is to employ delivery systems that allow selective antigen absorption and help modulate the immune response. This review aimed to discuss the influence of these different systems on the response generated by nucleic acid vaccines. The results indicate that delivery systems based on lipids, polymers, and microorganisms such as yeasts can be used to ensure the stability and transport of nucleic acid vaccines to their respective protein synthesis compartments. Thus, in view of the limitations of nucleic acid-based vaccines, it is important to consider the type of delivery system to be used—due to its impact on the immune response and desired final effect.

31 January 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
MIMaria da Conceição Viana Invenção
Maria da Conceição Viana Invenção
Larissa Silva de MacêdoLarissa Silva de Macêdo
Larissa Silva de Macêdo
Ingrid Andrêssa de MouraIngrid Andrêssa de Moura
Ingrid Andrêssa de Moura
LSLucas Santos
Lucas Santos
BEBenigno Cristofer Flores Espinoza
Benigno Cristofer Flores Espinoza
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas
Background: The rapid advancement of the pandemic caused by SARS-CoV-2 and its variants reinforced the importance of developing easy-to-edit vaccines with fast production, such as multi-epitope DNA vaccines. The present study aimed to construct a synthetic antigen multi-epitope SARS-CoV-2 to produce a DNA vaccine. Methods: A database of previously predicted Spike and Nucleocapsid protein epitopes was created, and these epitopes were analyzed for immunogenicity, conservation, population coverage, and molecular docking. Results: A synthetic antigen with 15 epitopes considered immunogenic, conserved even in the face of variants and that were able to anchor themselves in the appropriate HLA site, together had more than 90% worldwide coverage. A multi-epitope construct was developed with the sequences of these peptides separated from each other by linkers, cloned into the pVAX1 vector. This construct was evaluated in vivo as a DNA vaccine and elicited T CD4+ and T CD8+ cell expansion in the blood and spleen. In hematological analyses, there was an increase in lymphocytes, monocytes, and neutrophils between the two doses. Furthermore, based on histopathological analysis, the vaccines did not cause any damage to the organs analyzed. Conclusions: The present study generated a multi-epitope synthetic vaccine antigen capable of generating antibody-mediated and cellular immune responses.

7 November 2024 in Clinica Chimica Acta
Verified
Journal Article
Closed access
Vanessa Emanuelle Pereira SantosVanessa Emanuelle Pereira Santos
Vanessa Emanuelle Pereira Santos
PNPedro Luiz de França Neto
Pedro Luiz de França Neto
BIBeatriz Eda Isídio
Beatriz Eda Isídio
PFPedro Henrique Bezerra Fontes
Pedro Henrique Bezerra Fontes
Ingrid Andrêssa de MouraIngrid Andrêssa de Moura
Ingrid Andrêssa de Moura
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas